• Galmed Pharmaceuticals rebranded as Eocene, shifting its corporate identity toward a GI-focused biopharma and medical-device platform.
• Nasdaq ticker to change to EOCN, reflecting the new name and positioning.
• Strategic focus broadened following the Colospan acquisition, adding a commercial-stage colorectal surgery device business to its portfolio.
• Yorkville standby equity purchase agreement terminated; about $7.3 million raised via issuance of 437,947 ordinary shares.
• Cash and equivalents totaled $11.4 million as of June 30, 2026, including short-term deposits and marketable debt securities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609090730PR_NEWS_USPR_____LN43604) on September 09, 2026, and is solely responsible for the information contained therein.